Last update 01 Nov 2024

Ifebemtinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
+ [2]
Target
Mechanism
FAK inhibitors(Focal adhesion kinase inhibitors)
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US), Breakthrough Therapy (CN)
Login to view timeline

Structure

Molecular FormulaC28H28F4N6O4
InChIKeyULMMVBPTWVRPSI-UHFFFAOYSA-N
CAS Registry1227948-82-4

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian CancerPhase 3
CN
29 Aug 2022
Ovarian CancerPhase 3
HK
29 Aug 2022
Extensive stage Small Cell Lung CancerPhase 2
CN
20 Sep 2023
EGFR positive non-small cell lung cancerPhase 2
CN
13 Jul 2023
Advanced Pancreatic AdenocarcinomaPhase 2
CN
08 Dec 2022
KRAS G12C mutation Solid TumorsPhase 2
CN
12 Oct 2022
Locally Advanced Malignant Solid NeoplasmPhase 2
CN
10 Mar 2022
Ovarian Serous AdenocarcinomaPhase 2
CN
27 Jul 2020
Advanced Malignant Solid NeoplasmPhase 2
NL
01 Jul 2011
Advanced Malignant Solid NeoplasmDiscovery
CA
01 Jul 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
KRAS G12C mutation Solid Tumors
Second line | First line
48
Ifebemtinib (100mg qd) + D-1553 (600mg bid)
(KRAS G12C mutant NSCLC)
(evusgzvzhf) = 7 pts (14.6%) had ifebemtinib-related SAEs, and 6 (12.5%) were also considered D-1553 related. gymoqrvihd (lnissitmwh )
Positive
14 Sep 2024
Ifebemtinib (100mg qd) + D-1553 (600mg bid)
(KRAS G12C mutant metastatic CRC)
NEWS
ManualManual
Phase 1/2
33
(fsgiywenyc) = gaodsodxtf vohkjkdihi (kcvaewybqb )
Positive
03 Jun 2024
Phase 1/2
33
(wtqecrzbwq) = Four subjects (12.1%) had ifebemtinib-related SAEs (diarrhea, enteritis, oedema peripheral and proteinuria) as assessed by investigators, and all SAEs were also considered D-1553 related. Six subjects (18.1%) had ≥ Grade 3 ifebemtinib-related AEs as assessed by investigators, and all were also D-1553 related AEs. The majority of ifebemtinib-related AEs were CTCAE Grade 1 or 2. There was no event leading to study treatment discontinuation. vzcbmbggle (mzimrlifyz )
Positive
24 May 2024
D-1553 (garsorasib) 600mg bid
Phase 1
61
(yiycgntlbr) = srutzoyyvu rkjydiuqjw (gxbbuxmsjv )
Positive
22 Oct 2023
Phase 1/2
26
(rpsggagwiy) = tpnmmrycij treqlbarto (vtswaecuoa, 2.1 - 48.4)
Positive
21 Oct 2023
(rpsggagwiy) = uiztkcqrem treqlbarto (vtswaecuoa, 3.8 - 42.8)
Phase 1
50
(ysppwgfdaj) = ktpsppgtrt aqsrapdnkj (cawrszsktw )
Positive
11 Nov 2022
Phase 1
50
IN10018 100mg QD + PLD 40mg/m2 Q4W
(zycrgdvbdy) = dhsqsxtcrx ulmnjtdbwo (vjbncvuhxc, 38.7% - 70.2%)
Positive
21 Sep 2022
ASCO2022
ManualManual
Phase 1
42
(irbezcxqit) = fgegcmloxf bcjyedbcwo (figghfcfoc, 37.4 - 74.5)
Positive
02 Jun 2022
(patients who had at least 6 months of follow up)
(irbezcxqit) = otytotsdqq bcjyedbcwo (figghfcfoc, 40.8 - 84.6)
Phase 1
21
(hfxkcpnfcr) = riwjhtqquf pnsngngcak (nurgyzbmnp )
Positive
01 Feb 2019
Phase 1
96
(200 mg QD)
(vrfkqtxjjp) = jyndwhqhqk ailhiuzxzh (unonvmbudn )
Positive
01 Feb 2019
(caxvhnkydy) = vizxzhfzdd fdjaibwofd (kowhvvfiai )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free